In early 2013, the U.S. Food and Drug Administration did something almost unprecedented: it told women to take half the dose of one of the country's most popular sleeping pills. Zolpidem—sold as Ambien—had been on the market for two decades, taken by millions of men and women at the same dose. The drug hadn't changed. What changed was a belated discovery: women clear it from their blood far more slowly, leaving them impaired the next morning at the wheel. The pill was the same. The bodies were not—and almost no one had checked.

That quiet correction pointed at a much larger blind spot, one that shapes how we should think about every drug that was studied in one kind of body and then handed to another.

For sixteen years, women were largely left out

The gap has a startlingly specific origin. In 1977, after the thalidomide tragedy raised fears about harm to fetuses, the FDA issued guidance recommending that women "of childbearing potential" be excluded from early-phase drug trials. In practice the rule was sweeping—it swept in single women, women using contraception, women whose partners had been sterilized. For the better part of two decades, the people enrolled in early drug research were overwhelmingly men.

Underneath it sat an assumption rarely said out loud: that a male body was a good enough stand-in for all bodies, and that women were essentially smaller men with inconvenient hormones. It was not until 1993 that the dam broke. The FDA reversed its 1977 guidance, and Congress passed the NIH Revitalization Act, which required federally funded studies to include women in numbers large enough to actually analyze differences between the sexes.

Same drug, different body

Why does it matter who a drug was tested on? Because sex is not a cosmetic variable in pharmacology—it reaches into how a body absorbs, distributes, and breaks down a medicine.

Women, on average, have a higher proportion of body fat and a different balance of the liver enzymes that dismantle drugs. The zolpidem case made this concrete: women showed roughly 50% higher morning blood levels than men on an identical dose, which is why the recommended starting dose was cut from 10 mg to 5 mg for women while men's stayed the same. More broadly, women report adverse drug reactions more often than men—an unsurprising result when many doses were calibrated, decades ago, on male volunteers. The "standard dose" was never truly neutral. It was a male dose wearing a universal label.

Now connect it to the pink pill

This is exactly where products marketed as "female" versions of male drugs run into trouble. Sildenafil—the molecule in Viagra—was developed, dosed, and proven in men, for a male condition. Its familiar 100 mg strength is the maximum single dose worked out in male trials.

When that same molecule is simply dyed pink and sold as a Lady Era sildenafil tablet "for women," it doesn't arrive with a female evidence base—it inherits the male one. The dose is the male maximum; the safety data were gathered in men; no dedicated study established what the right amount is for a woman taking it for the first time. There's a particularly pointed irony here: sildenafil is broken down chiefly by the liver enzyme CYP3A4, one of the very enzymes whose activity differs between the sexes—the same kind of difference that forced the zolpidem change. Yet for sildenafil repackaged for women, that question was never properly asked. A 100 mg male-calibrated dose handed to a woman with no female dosing study behind it is the sex gap in miniature.

Why this is slowly changing

The picture is improving. Regulators and funders now push for sex to be treated as a biological variable from the earliest, animal stages of research onward, and women are enrolled in trials in far greater numbers than in the 1980s. But progress is uneven: as recently as the last few years, analyses have found women still underrepresented in trials for several major diseases. The default is being dismantled—just slowly, and not yet everywhere.

The real takeaway

The lesson of the Ambien correction isn't really about one sleeping pill. It's that "the same dose for everyone" quietly meant "the dose that suited men," and that closing the gap takes actual data, not a change of color. A pink coating on a male-tested molecule doesn't generate the missing studies; it just hides their absence.

For any individual woman, that's the strongest argument for a real consultation over a self-prescribed tablet bought online. A clinician can weigh her physiology, her other medications, and her actual diagnosis—the very things the historical research record so often skipped, and the things a one-size-fits-all pill was never designed to know.

References

1. NIH Office of Research on Women's Health / AAMC—history of women's inclusion in clinical research (1977 FDA exclusion guidance; 1993 reversal and NIH Revitalization Act).
2. U.S. Food and Drug Administration. Drug Safety Communication on zolpidem (2013)—sex-specific dose reduction.
3. U.S. Pharmacist / peer-reviewed reviews on sex differences in pharmacokinetics, including CYP3A4 activity and body composition.
4. NIH Revitalization Act of 1993 and the "Sex as a Biological Variable" policy.

This article is for general educational purposes and is not medical advice. Sildenafil-based products are prescription medicines; always consult a qualified healthcare professional before starting, stopping, or combining any medication.